Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 17/20 | 0.63 |
| ▸ | LCK | P06239 | 3/20 | 0.63 |
| ▸ | TXK | P42681 | 3/20 | 0.63 |
| ▸ | SYK | P43405 | 3/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27645976 | 0.90 | ITK (0.54) | ITKLCKTXKSYKCASP3 | |
| SCHEMBL1622817 | 0.89 | ITK (0.65) | ITKLCKTXKSYK | |
| SCHEMBL12748758 | 0.86 | ITK (0.64) | ITKLCKTXKSYKCASP3 | |
| SCHEMBL1622508 | 0.86 | ITK (0.61) | ITKLCKTXKSYK | |
| SCHEMBL13869803 | 0.81 | ITK (0.60) | ITKLCKTXKSYKPARP1 | |
| SCHEMBL27645971 | 0.80 | ITK (0.62) | ITKLCKTXKSYK | |
| SCHEMBL1620556 | 0.80 | ITK (0.51) | ITKLCKTXKSYK | |
| SCHEMBL2918537 | 0.80 | ITK (0.50) | ITKLCKTXKSYKCASP3 | |
| SCHEMBL1621146 | 0.79 | ITK (0.48) | ITKLCKTXKSYKCASP3 | |
| SCHEMBL27667060 | 0.79 | ITK (0.61) | ITKLCKTXKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | claimed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | claimed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| CN-100398545-C | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2008-07-02 | — | — | CN | claimed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | claimed |
| JP-2007505038-A | — | — | 2007-03-08 | — | — | JP | claimed |
| CN-1849322-A | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1682553-A1 | THIENOPYRAZOLES | Aventis Pharmaceuticals Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005026175-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| CN-100398545-C | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2008-07-02 | — | — | CN | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| CN-1849322-A | Thienopyrazoles | AVENTIS PHARMA INC (US) | 2006-10-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | ITK 1/4885LCK 46/4885TXK 6/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | ITK 1/4885LCK 59/4885TXK 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.